Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Adaptive Immunity
/ immunology
Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
BNT162 Vaccine
/ immunology
COVID-19
/ immunology
Diabetes Mellitus, Type 2
/ immunology
Female
Humans
Immunoglobulin G
/ blood
Male
Middle Aged
SARS-CoV-2
/ genetics
Vaccination
Young Adult
BNT162b2
COVID-19
COVID-19 vaccine
T2D
antibodies
diabetes mellitus type 2
mRNA vaccine
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
08
2021
accepted:
02
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
28
12
2021
Statut:
epublish
Résumé
The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer-BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1
Identifiants
pubmed: 34899701
doi: 10.3389/fimmu.2021.752233
pmc: PMC8652288
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
752233Informations de copyright
Copyright © 2021 Ali, Alterki, Sindhu, Alahmad, Hammad, Al-Sabah, Alghounaim, Jamal, Aldei, Mairza, Husain, Deverajan, Ahmad, Cherian, Alkhairi, Alkandari, Abubaker, Abu-Farha and Al-Mulla.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Heliyon. 2021 Apr;7(4):e06706
pubmed: 33842709
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Front Immunol. 2020 Jul 10;11:1708
pubmed: 32754163
Sci Rep. 2021 Mar 10;11(1):5563
pubmed: 33692457
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Vaccines (Basel). 2021 Jan 29;9(2):
pubmed: 33572702
PLoS One. 2021 Jun 16;16(6):e0249499
pubmed: 34133415
Vaccines (Basel). 2021 May 11;9(5):
pubmed: 34064613
Vaccines (Basel). 2021 Jun 18;9(6):
pubmed: 34207300
Clin Chem Lab Med. 2021 Apr 12;59(9):1585-1591
pubmed: 33838087
EClinicalMedicine. 2021 Jun;36:100928
pubmed: 34109307
Front Biosci. 2008 May 01;13:5187-94
pubmed: 18508580
Diabetes Care. 2020 Dec;43(12):3113-3116
pubmed: 33051331
Eur J Med Res. 2013 May 01;18:12
pubmed: 23634778
Open Biol. 2020 Sep;10(9):200160
pubmed: 32961074
Diabetes Metab Syndr. 2021 Mar-Apr;15(2):505-508
pubmed: 33662837
Front Immunol. 2020 Jul 22;11:1582
pubmed: 32793223
Prim Care Diabetes. 2021 Feb;15(1):18-20
pubmed: 32800450
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):193-196
pubmed: 33385765
Diabetologia. 2020 Dec;63(12):2548-2558
pubmed: 33029657
Clin Chim Acta. 2021 Aug;519:60-63
pubmed: 33857476
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
PLoS One. 2020 Nov 20;15(11):e0242768
pubmed: 33216801
Front Immunol. 2020 Dec 01;11:576818
pubmed: 33335527
Mol Aspects Med. 2013 Feb;34(1):12-29
pubmed: 23068074
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279